ReviewDiabetologia2021
Pharmacogenetics of novel glucose-lowering drugs.
Review in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.Pharmacogenomics · 2023Pooled it
- How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.Diabetologia · 2023Trial
- Comparative effectiveness of subcutaneous GLP-1 receptor agonists versus SGLT2 inhibitors on metabolic and hepatic outcomes in T2DM with MASLD: a propensity score-matched study.Journal of endocrinological investigation · 2026Article
- Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden.Toxicology reports · 2026Review
- Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Techniques for the determination of dipeptidyl peptidase IV and screening of its inhibitors.Journal of pharmaceutical analysis · 2026Review
- Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events.BMC medical genomics · 2026Article
- Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.Journal of personalized medicine · 2026Review
- New Treatment Options for MASLD Patients with Type 2 Diabetes.Life (Basel, Switzerland) · 2026Review
- Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Acta diabetologica · 2026Article
- Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors.European journal of medical research · 2026Article
- Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists.Diabetology & metabolic syndrome · 2025Review
- The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.Endocrine · 2025Article
- Diabetes in China: epidemiology, pathophysiology and multi-omics.Nature metabolism · 2025 · on this mapReview
- Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women.Journal of orthopaedic surgery and research · 2024Article
- Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.Diabetes, obesity & metabolism · 2023Article
- Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.Molecular biology reports · 2023Review
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.Diabetes, obesity & metabolism · 2023Article
- Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.medRxiv : the preprint server for health sciences · 2023Article
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.medRxiv : the preprint server for health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). In total, 22 studies were retrieved from the literature (MEDLINE). Variants of the GLP-1 receptor gene (GLP1R) were associated with a smaller reduction in HbA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.